In addition, considering the discussed data, it is probably reasonable to administer loop diuretics in those patients with signs or symptoms of congestion; ARB in patients with left ventricular hypertrophy, hypertension, or concomitant diabetic kidney disease and SGLT-2 inhibitors in all reliable patients with DHFpEF to treat diabetes, reduce the risk of heart failure-related hospitalizations and cardiovascular mortality, and improve renal outcomes. The gene discussed is SLC5A2; the disease is diabetic kidney disease.